David Preiss

• Pooled Safety Analysis of Evolocumab in Over 6000 Patients from Double-Blind and Open-label Extension Studies

  Preiss D., (2017), Circulation

• Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction. A report from the Irbesartan in Heart Failure with Preserved Ejection Fraction trial (I-Preserve).

  Preiss D., (2017), Circulation

• Interpretation of the evidence for the efficacy and safety of statin therapy.

  Collins R. et al, (2016), Lancet, 388, 2532 - 2561

• Cholesterol- and blood pressure-lowering drug use for secondary cardiovascular prevention in 2004 - 2013 Europe

  Mihaylova BN. et al, (2016), European Journal of Preventive Cardiology

• Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.

  Rankin NJ. et al, (2016), Int J Epidemiol, 45, 1351 - 1371

• Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes.

  White J. et al, (2016), JAMA cardiology

• SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

  Sattar N. et al, (2016), Diabetologia, 59, 1333 - 1339

• Metformin Therapy and Circulating NT-proBNP Levels: The CAMERA Trial

  Preiss D., (2016), Diabetes Care

• Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies.

  Loomis AK. et al, (2016), J Clin Endocrinol Metab, 101, 945 - 952

• THE RELATIONSHIP BETWEEN CIRCULATING MICRORNA AND LIPID INDICES

  Eastwood J. et al, (2016), ATHEROSCLEROSIS, 245, E248 - E248

• Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

  Sattar N. et al, (2016), The Lancet Diabetes & Endocrinology

• Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.

  Kristensen SL. et al, (2016), Circ Heart Fail, 9

• Biochemistry laboratories should routinely report non-HDL-cholesterol.

  Preiss D. and Neely D., (2015), Ann Clin Biochem, 52, 629 - 631

• Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus

  Sattar N. et al, (2015), DIABETOLOGIA, 58, S79 - S79

• Efficacy of one year of treatment with the PCSK9 inhibitor evolocumab (AMG 145) in 4,802 subjects with or without type 2 diabetes

  Preiss D. et al, (2015), DIABETOLOGIA, 58, S80 - S80

• Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.

  Preiss D. et al, (2015), BMJ Open, 5

• Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials.

  Rush CJ. et al, (2015), JACC Heart Fail, 3, 603 - 614

• Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure.

  Jackson CE. et al, (2015), JACC Heart Fail, 3, 618 - 625

• THE EFFECT OF STATIN THERAPY ON HEART FAILURE EVENTS: A COLLABORATIVE META-ANALYSIS OF UNPUBLISHED DATA FROM MAJOR RANDOMIZED TRIALS

  Preiss D. et al, (2015), ATHEROSCLEROSIS, 241, E21 - E21

• THE EFFECT OF METFORMIN ON THE LIPOPROTEIN PROFILE AND LIPOPROTEIN PARTICLE SIZE IN THE CAROTID ATHEROSCLEROSIS: METFORMIN FOR INSULIN RESISTANCE (CAMERA) TRIAL

  Rankin N. et al, (2015), ATHEROSCLEROSIS, 241, E68 - E68

• SYSTEMATIC REVIEW OF STUDIES EXPLORING REASONS FOR STATIN NON-ADHERENCE AND OF RANDOMISED CONTROLLED TRIALS OF INTERVENTIONS TO IMPROVE ADHERENCE

  Logue J. et al, (2015), ATHEROSCLEROSIS, 241, E52 - E52

• HMG-COENZYME A REDUCTASE INHIBITION, TYPE 2 DIABETES, AND BODYWEIGHT: EVIDENCE FROM GENETIC ANALYSIS AND RANDOMISED TRIALS

  Swerdlow D. et al, (2015), ATHEROSCLEROSIS, 241, E17 - E17

• CIRCULATING MICRORNA-30C IS ASSOCIATED WITH TOTAL- AND LDL-CHOLESTEROL

  Sodi R. et al, (2015), ATHEROSCLEROSIS, 241, E121 - E121

• The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.

  Preiss D. et al, (2015), Eur Heart J, 36, 1536 - 1546

• Mendelian randomisation study for statin treatment - Authors' reply.

  Swerdlow DI. et al, (2015), Lancet, 385

• The new pooled cohort equations risk calculator.

  Preiss D. and Kristensen SL., (2015), Can J Cardiol, 31, 613 - 619

• Does the LDL receptor play a role in the risk of developing type 2 diabetes?

  Preiss D. and Sattar N., (2015), JAMA, 313, 1016 - 1017

• The effect of metformin on circulating amino acids in the Carotid Atherosclerosis: Metformin for insulin Resistance (CAMERA) trial reveals a novel effect on four amino acids

  Rankin N. et al, (2015), DIABETIC MEDICINE, 32, 12 - 12

• Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.

  Kristensen SL. et al, (2015), Eur J Heart Fail, 17, 169 - 176

• Classification of reported statin intolerance.

  Preiss D. and Sattar N., (2015), Curr Opin Lipidol, 26, 65 - 66

• HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.

  Swerdlow DI. et al, (2015), Lancet, 385, 351 - 361

• Reducing cardiovascular risk in type 2 diabetes mellitus

  Preiss D. and Sattar N., (2015), 43, 7 - 12

• Physical activity as a determinant of fasting and 2-h post-challenge glucose: A prospective cohort analysis of the NAVIGATOR trial

  Yates T. et al, (2015), Diabetic Medicine, 32, 1090 - 1096

• Biomarkers Of vascular inflammation and cardiovascular disease

  Welsh P. et al, (2015), Arterial Disorders: Definition, Clinical Manifestations, Mechanisms and Therapeutic Approaches, 115 - 136

• Biomarkers of hypertension and cardiovascular disease

  Welsh P. et al, (2015), 2015-January, 119 - 136

• Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up.

  Welsh P. et al, (2014), Diabetologia, 57, 2513 - 2520

• Treatment of severe hypertriglyceridaemia.

  Preiss D. et al, (2014), Lancet Diabetes Endocrinol, 2

• The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective.

  Rankin NJ. et al, (2014), Atherosclerosis, 237, 287 - 300

• Do statins reduce microvascular complications in diabetes?

  Preiss D., (2014), Lancet Diabetes Endocrinol, 2, 858 - 859

• Non-alcoholic fatty liver disease.

  Sattar N. et al, (2014), BMJ, 349

• Emerging therapeutic approaches to treat dyslipidemia.

  Preiss D. and Packard CJ., (2014), Curr Cardiol Rep, 16

• Insulin resistance is a risk factor for diabetes but not cardiovascular disease in the elderly: results from long-term follow-up of the Prospective Study of Pravastatin in the Elderly at Risk trial

  Welsh P. et al, (2014), DIABETIC MEDICINE, 31, 36 - 36

• Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): A randomised controlled trial

  Preiss D. et al, (2014), The Lancet Diabetes and Endocrinology, 2, 116 - 124

• Letters: Fomepizole and ethanol for treating ethylene glycol poisoning

  Preiss D., (2014), BMJ (Online), 348

• Change in levels of physical activity after diagnosis of type 2 diabetes: An observational analysis from the NAVIGATOR study

  Preiss D. et al, (2014), Diabetes, Obesity and Metabolism, 16, 1265 - 1268

• Choice of medical therapy to lower triglycerides in those at risk of pancreatitis.

  Preiss D. and Sattar N., (2013), Curr Opin Lipidol, 24, 532 - 533

• Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

  Preiss D. et al, (2013), Stroke, 44, 2590 - 2593

• Effect of rosuvastatin on fatigue in patients with heart failure.

  Perez AC. et al, (2013), J Am Coll Cardiol, 61, 1121 - 1122

• Triglyceride levels, pancreatitis and choice of lipid-modifying therapy.

  Preiss D., (2013), Expert Rev Gastroenterol Hepatol, 7, 193 - 195

• Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.

  Preiss D. et al, (2012), JAMA, 308, 804 - 811

• Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).

  Preiss D. et al, (2012), Eur J Heart Fail, 14, 909 - 915

• Statin therapy and new-onset diabetes: a cause for concern?

  Preiss D., (2012), Maturitas, 72, 95 - 96

• HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards.

  Sattar N. and Preiss D., (2012), Diabetologia, 55, 1564 - 1567

• Pharmacotherapy: Statins and new-onset diabetes--the important questions.

  Preiss D. and Sattar N., (2012), Nat Rev Cardiol, 9, 190 - 192

• Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.

  Preiss D. et al, (2012), BMJ Open, 2

• The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes.

  Ford I. et al, (2011), Int J Epidemiol, 40, 1530 - 1538

• Statins and the risk of new-onset diabetes: a review of recent evidence.

  Preiss D. and Sattar N., (2011), Curr Opin Lipidol, 22, 460 - 466

• Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

  Shyangdan D. et al, (2011), Health Technol Assess, 15, 1 - 110

• Statin therapy dose and risk of new-onset diabetes - Reply

  Preiss D. et al, (2011), JAMA - Journal of the American Medical Association, 306

• Intensive glucose lowering treatment in type 2 diabetes.

  Preiss D. and Ray KK., (2011), BMJ, 343

• The case for diabetes screening: ADDITION-Europe.

  Preiss D. and Sattar N., (2011), Lancet, 378, 106 - 108

• Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

  Preiss D. et al, (2011), JAMA, 305, 2556 - 2564

• Reply

  Ghouri NA. et al, (2011), Hepatology, 53

• Combined cardiovascular and diabetes risk assessment in primary care.

  Preiss D. et al, (2011), Diabet Med, 28, 19 - 22

• A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design.

  Preiss D. et al, (2011), Am Heart J, 161, 210 - 219.e1

• HbA1c: a useful cardiovascular risk marker in those without diabetes?

  Preiss D. and Sattar N., (2010), Diabetologia, 53, 2468 - 2469

• Reducing cardiovascular risk in type 2 diabetes mellitus

  Preiss D. and Sattar N., (2010), 38, 632 - 637

• Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data.

  Ghouri N. et al, (2010), Hepatology, 52, 1156 - 1161

• Statins and risk of incident diabetes - Authors' reply

  Sattar N. et al, (2010), The Lancet, 375, 2141 - 2142

• Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up.

  Preiss D. et al, (2010), Eur Heart J, 31, 1230 - 1236

• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

  Sattar N. et al, (2010), Lancet, 375, 735 - 742

• Event rates in trials of patients with type 2 diabetes.

  Preiss D. et al, (2010), JAMA, 303, 732 - 733

• Metformin and lactic acidosis. Metformin: framed again?

  Preiss DJ. and Sattar N., (2009), BMJ, 339

• Authors' reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: Be careful

  Preiss D. and Sattar N., (2009), Clinical Endocrinology, 71, 456 - 457

• Intensive glucose control and cardiovascular outcomes - Authors' reply

  Ray KK. et al, (2009), The Lancet, 374

• Intensive glucoselowering and cardiovascular disease

  Preiss D., (2009), Diabetes and Primary Care, 11

• Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.

  Preiss D. and Sattar N., (2009), Clin Endocrinol (Oxf), 70, 815 - 828

• Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.

  Ray KK. et al, (2009), Lancet, 373, 1765 - 1772

• Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.

  Preiss D. et al, (2009), Diabetes Care, 32, 915 - 920

• Metabolic syndrome: collapsing under its own weight?

  Preiss D. and Sattar N., (2009), Diabet Med, 26, 457 - 459

• The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome.

  Preiss D. et al, (2008), Int J Clin Pract, 62, 1337 - 1343

• Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations.

  Preiss D. and Sattar N., (2008), Clin Sci (Lond), 115, 141 - 150

• Diagnosing unsuspected hypopituitarism in adults from suggestive thyroid function test results.

  Preiss D. et al, (2008), Ann Clin Biochem, 45, 70 - 75

• The influence of a cooked-meat meal on estimated glomerular filtration rate

  Preiss DJ. et al, (2007), Annals of Clinical Biochemistry, 44, 35 - 42

• Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence

  Preiss D. and Sattar N., (2006), Heart, 93, 1493 - 1496

• How to measure renal function in clinical practice: Eating cooked meat alters serum creatinine concentration and eGFR significantly

  Preiss DJ. et al, (2006), BMJ, 333, 1072 - 1072

• Ambient temperature and pseudohyperkalaemia

  Preiss D. and Gunn I., (2006), Annals of Clinical Biochemistry, 43, 326 - 327

• Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?

  Preiss DJ. and Sattar N., International Journal of Clinical Practice

• The sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes

  Preiss D. and Holman R., Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics

• The insulin resistance syndrome

  Preiss D. et al, International Textbook of Diabetes Mellitus

• The incremental prognostic and clinical value of multiple novel biomarkers in heart failure

  Preiss D., European Journal of Heart Failure

• Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing

  Preiss D., Lancet Diabetes and Endocrinology

• Prediction of Cardiovascular Disease Risk by Cardiac Biomarkers in 2 United Kingdom Cohort Studies

  Welsh P. et al, Hypertension, HYPERTENSIONAHA.115.06501 - HYPERTENSIONAHA.115.06501

• PCSK9 inhibition: the dawn of a new age in cholesterol lowering?

  Preiss D. and Mafham M., Diabetologia

• PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study

  Preiss D. et al, The Lancet Diabetes and Endocrinology

• Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials

  Goldie C. et al, Heart, heartjnl-2015-308055 - heartjnl-2015-308055

• Genetic insights into statin-associated diabetes risk

  Preiss D., Current Opinion in Lipidology

• Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

  Preiss D., JAMA

• Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

  Preiss D., Cardiovascular Drugs and Therapy

• Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

  Preiss D., BMC Nephrology

• Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study

  Preiss DJ., Diabetic Medicine

• Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure

  Preiss D., Lancet Diabetes and Endocrinology

• Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial

  Preiss D., Clinical Cardiology

Key publications

• Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

  Sattar N. et al, (2016), The Lancet Diabetes & Endocrinology

• The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.

  Preiss D. et al, (2015), Eur Heart J, 36, 1536 - 1546

• HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.

  Swerdlow DI. et al, (2015), Lancet, 385, 351 - 361

• Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): A randomised controlled trial

  Preiss D. et al, (2014), The Lancet Diabetes and Endocrinology, 2, 116 - 124

• Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

  Preiss D. et al, (2011), JAMA, 305, 2556 - 2564

• Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.

  Preiss D. et al, (2012), JAMA, 308, 804 - 811

Recent Publications

• Pooled Safety Analysis of Evolocumab in Over 6000 Patients from Double-Blind and Open-label Extension Studies

  Preiss D., (2017), Circulation

• Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction. A report from the Irbesartan in Heart Failure with Preserved Ejection Fraction trial (I-Preserve).

  Preiss D., (2017), Circulation

• Interpretation of the evidence for the efficacy and safety of statin therapy.

  Collins R. et al, (2016), Lancet, 388, 2532 - 2561

• Cholesterol- and blood pressure-lowering drug use for secondary cardiovascular prevention in 2004 - 2013 Europe

  Mihaylova BN. et al, (2016), European Journal of Preventive Cardiology

• Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.

  Rankin NJ. et al, (2016), Int J Epidemiol, 45, 1351 - 1371